Thromb Haemost 2000; 84(03): 420-423
DOI: 10.1055/s-0037-1614038
Commentary
Schattauer GmbH

Folate Administration Increases n-3 Polyunsaturated Fatty Acids in Rat Plasma and Tissue Lipids

María-Luisa Pita
1   From Departamento de Bioquímica Médica y Biología Molecular, Spain
,
María-José Delgado
2   Departamento de Fisiología y Biología Animal, Universidad de Sevilla, Spain
› Author Affiliations
Further Information

Publication History

Received 19 November 1999

Accepted after resubmission 17 April 2000

Publication Date:
14 December 2017 (online)

Summary

It has been shown that folic acid deficiency can modify polyunsaturated fatty acid (PUFA) metabolism and thus could contribute to the development of cardiovascular diseases. We have studied the effect of folate administration on fatty acid composition of plasma, platelet, erythrocyte, intestinal and liver lipids. Two groups of rats were daily injected with either saline solution (control group) or 5-methyl-tetrahydrofolate (MTHF) solution (MTHF group) for 15 days. Changes induced by folate treatment on n-6 PUFA were not very significant. Linoleic acid only decreased in liver and intestinal phospholipids of MTHF rats whereas arachidonic acid was unaffected by folate administration. However, n-3 PUFA significantly increased in plasma lipid fractions and in platelet, erythrocyte and intestinal phospholipids. It is well known that n-3 PUFA show antithrombotic properties. Thus, the increase of n-3 PUFA observed after MTHF administration might contribute to the prevention of vascular disorders.

 
  • References

  • 1 Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
  • 2 Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
  • 3 McCully KS. Vascular pathology of homocysteinemia. Am J Pathol 1969; 56: 111-28.
  • 4 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
  • 5 Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Bo RCP, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins AL, Gore TB, Cornwell PE, Roseman JM. Plasma homocysteine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-8.
  • 6 Boushey CJ, Beresford ASS, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits on increasing folic acid intakes. JAMA 1995; 274: 1049-57.
  • 7 den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
  • 8 Duell PB, Malinow MR. Homocysteine: an important risk factor for atherosclerotic vascular disease. Curr Op Lipidol 1997; 08: 28-34.
  • 9 Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520-2.
  • 10 Verhoef P, Stampfer MJ, Rimm EB. Folate and coronary heart disease. Curr Op Lipidol 1998; 09: 17-22.
  • 11 Arnadottir M, Brattstrom L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-40.
  • 12 Ubbink JB. The role of vitamins in the pathogenesis and treatment of hyperhomocysteinemia. J Inherit Metab Dis 1997; 20: 316-325.
  • 13 den Heijer M, Brower IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
  • 14 Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231-43.
  • 15 Durand P, Prost M, Blache D. Folic acid deficiency enhances oral contraceptive-induced platelet hyperactivity. Arterioscler Thromb Vasc Biol 1997; 17: 1939-46.
  • 16 Pita M-L, Rubio J-M, Murillo M-L, Carreras O, Delgado M-J. Chronic alcoholism decreases polyunsaturated fatty acid levels in human plasma, erythrocytes, and platelets-Influence of chronic liver disease. Thromb Haemost 1997; 78: 808-12.
  • 17 Hirose S, Kim S, Matsuda A, Itakura Y, Matsumura O, Tamura H, Nagasawa R, Mitarai T, Isoda K. Effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients: effects on unsaturated fatty acids. Nippon Jinzo Gakkai Shi 1998; 40: 8-16.
  • 18 Hanahan DJ, Ekholm JE. The preparation of red cell ghosts. In Methods in Enzymology. Fleischer S, Packer L. eds. New York & London: Academic Press; 1974. vol XXXI (Part A) 168-172.
  • 19 Folch J, Lees M, Stanley GSH. A simple method for the isolation and purification of the total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
  • 20 Skipski VP, Barclay M. Thin-layer chromatography of lipids. In: Methods in Enzymology. Lowenstein JM. ed. New York & London: Academic Press; 1969. vol XIV: 548-50.
  • 21 Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1987; 27: 114-20.
  • 22 Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am J Clin Nutr 1990; 52: 1-28.
  • 23 Goodnight SH, Cairns JA, Fischer M, Fitzgerald GA. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. Chest 1992; 102: 374-84S.
  • 24 Miles EA, Calder PC. Modulation of immune function by dietary fatty acids. Proc Nutr Soc 1998; 57: 277-92.
  • 25 Brossard N, Crosset M, Pachiaudi C, Riou JP, Tayot JL, Lagarde M. Retroconversion and metabolism of 13C, 22 : 6 n-3 in humans and rats after intake of a simple dose of 13C,22:6n-3 triacylglycerols. Am J Clin Nutr 1996; 64: 577-86.
  • 26 Conquer JA, Holub BJ. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997; 32: 341-5.
  • 27 Huang Y-S, Cunnane SC, Horrobin DF. Effect of different dietary proteins on plasma and liver fatty acid composition in growing rats. Proc Soc Exp Biol Med 1986; 181: 399-403.
  • 28 Sugano M, Ishida T, Koba K. Protein-fat interaction on serum cholesterol level, fatty acid desaturation and eicosanoid production in rats. J Nutr 1988; 118: 548-54.
  • 29 Sugiyama K, Yamakawa A, Kumazawa A, Saeki S. Methionine content of dietary proteins affects the molecular species composition of plasma phosphatidylcholine in rats fed a cholesterol-free diet. J Nutr 1997; 127: 600-7.
  • 30 Sugiyama K, Kumazawa A, Zhou H, Saeki S. Dietary methionine level affects linoleic acid metabolism through phosphatidylethanolamine N-methylation in rats. Lipids 1998; 33: 235-42.